Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC64662HelichrysetinCAS: 62014-87-3纯度: >99.00%
Helichrysetin,分离于 Helichrysum odoratissimum 的花朵中, 是一种ID2 (DNA 结合抑制剂 2) 抑制剂,可抑制DCIS (原位导管癌) 的形成。Helichrysetin 对细胞生长具有很强的抑制作用,并且能够诱导 A549 细胞凋亡 (apoptosis)。
- GC6472610-Formyl-5,8-dideazafolic acidCAS: 61038-31-1纯度: >96.00%
10-Formyl-5,8-dideazafolic acid 是一种胸苷酸合成酶 (thymidylate synthase) 抑制剂。
- GC647623,6-DihydroxyflavoneCAS: 108238-41-1纯度: >98.00%
3,6-Dihydroxyflavone 是一种抗癌剂。3,6-Dihydroxyflavone 剂量和时间依赖性地降低细胞活力并通过激活半胱天冬酶级联、切割聚 (ADP-核糖) 聚合酶 (PARP) 诱导 apoptosis。3,6-Dihydroxyflavone 增加细胞内氧化应激和脂质过氧化。
- GC64767ISIS 104838CAS: 250755-32-9
ISIS 104838是一种反义寡核苷酸药物,可减少肿瘤坏死因子 (TNF-alpha) 的产生。TNF-alpha 可以导致类风湿关节炎关节疼痛和肿胀。
- GC64786HellebrigeninCAS: 465-90-7
Hellebrigenin,属于心脏活性类固醇的丁二烯内酯之一,从中药中分离出来。Hellebrigenin 诱导 DNA 损伤和细胞周期 G2/M 阻滞。 Hellebrigenin 触发线粒体介导的细胞凋亡。
- GC64839VarlilumabCAS: 1393344-72-3纯度: >96.00%
Varlilumab (CDX-1127) 是一种首创的人 IgG1 抗 CD27 单克隆抗体。Varlilumab 具有抗肿瘤活性。
- GC64855PD-1/PD-L1-IN-23CAS: 2597056-04-5纯度: >99.00%
PD-1/PD-L1-IN-23 是一种有效的、具有口服活性的 PD-1/PD-L1 抑制剂。PD-1/PD-L1-IN-23 是 L7 的酯类前药。L7 是一种苯并[c][1,2,5]恶二唑衍生物,在生物学上被评估为 PD-L1 的抑制剂。PD-1/PD-L1-IN-23 在同基因和 PD-L1 人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。
- GC64993Chicoric acidCAS: 6537-80-0纯度: >98.00%
Chicoric acid是一种羟基肉桂酸,属于苯丙醇类有机化合物,存在于菊苣、 蒲公英和罗勒等多种植物中,具有抗氧化、抗炎、抗糖尿病、抗病毒等多种生物活性。
- GC65004Apostatin-1CAS: 2559703-06-7纯度: >99.00%
Apostatin-1 (Apt-1) is a novel TRADD inhibitor. Apostatin-1 binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N). Apostatin-1 inhibits bortezomib-induced apoptosis and RIPK1-dependent apoptosis (RDA) with an IC50 of about 1 μM.
- GC65010Bortezomib-d8纯度: >98.00%
Bortezomib-d8 (PS-341-d8) 是 Bortezomib 的氘代物。Bortezomib (PS-341) 是一种可逆性和选择性的蛋白酶体 (proteasome) 抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki=0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是第一种蛋白酶体抑制剂,具有抗癌活性。
- GC65033TislelizumabCAS: 1858168-59-8纯度: >97.50%
Tislelizumab 是一种对 PD-1 受体具有高结合亲和力的单克隆抗体,可最大限度地减少 Fcγ 受体与巨噬细胞的结合,从而消除抗体依赖性吞噬作用,这是一种 T 细胞清除机制,可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC64662 | Helichrysetin | 62014-87-3 | >99.00% | |
Helichrysetin,分离于 Helichrysum odoratissimum 的花朵中, 是一种ID2 (DNA 结合抑制剂 2) 抑制剂,可抑制DCIS (原位导管癌) 的形成。Helichrysetin 对细胞生长具有很强的抑制作用,并且能够诱导 A549 细胞凋亡 (apoptosis)。 | ||||
| GC64674 | ABBV-167 | 1351456-78-4 | >98.00% | |
ABBV-167 是一种 BCL-2 抑制剂 venetoclax 的磷酸盐前药。 | ||||
| GC64726 | 10-Formyl-5,8-dideazafolic acid | 61038-31-1 | >96.00% | |
10-Formyl-5,8-dideazafolic acid 是一种胸苷酸合成酶 (thymidylate synthase) 抑制剂。 | ||||
| GC64762 | 3,6-Dihydroxyflavone | 108238-41-1 | >98.00% | |
3,6-Dihydroxyflavone 是一种抗癌剂。3,6-Dihydroxyflavone 剂量和时间依赖性地降低细胞活力并通过激活半胱天冬酶级联、切割聚 (ADP-核糖) 聚合酶 (PARP) 诱导 apoptosis。3,6-Dihydroxyflavone 增加细胞内氧化应激和脂质过氧化。 | ||||
| GC64767 | ISIS 104838 | 250755-32-9 | - | |
ISIS 104838是一种反义寡核苷酸药物,可减少肿瘤坏死因子 (TNF-alpha) 的产生。TNF-alpha 可以导致类风湿关节炎关节疼痛和肿胀。 | ||||
| GC64768 | PK9327 | 2413987-20-7 | >98.00% | |
PK9327 是一种小分子稳定剂,靶向空腔的 p53 癌症突变。 | ||||
| GC64786 | Hellebrigenin | 465-90-7 | - | |
Hellebrigenin,属于心脏活性类固醇的丁二烯内酯之一,从中药中分离出来。Hellebrigenin 诱导 DNA 损伤和细胞周期 G2/M 阻滞。 Hellebrigenin 触发线粒体介导的细胞凋亡。 | ||||
| GC64839 | Varlilumab | 1393344-72-3 | >96.00% | |
Varlilumab (CDX-1127) 是一种首创的人 IgG1 抗 CD27 单克隆抗体。Varlilumab 具有抗肿瘤活性。 | ||||
| GC64855 | PD-1/PD-L1-IN-23 | 2597056-04-5 | >99.00% | |
PD-1/PD-L1-IN-23 是一种有效的、具有口服活性的 PD-1/PD-L1 抑制剂。PD-1/PD-L1-IN-23 是 L7 的酯类前药。L7 是一种苯并[c][1,2,5]恶二唑衍生物,在生物学上被评估为 PD-L1 的抑制剂。PD-1/PD-L1-IN-23 在同基因和 PD-L1 人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。 | ||||
| GC64862 | Tricetin | 520-31-0 | - | |
Tricetin 是一种有效的竞争性 Keap1-Nrf2 蛋白相互作用 (PPI) 抑制剂。Tricetin 作用于帕金森病模型,通过激活 Nrf2/HO-1 信号通路和阻止线粒体依赖性细胞凋亡 (apoptosis) 通路来保护 6-OHDA 诱导的神经毒性。 | ||||
| GC64864 | EJMC-1 | 397281-20-8 | - | |
EJMC-1 是一种中度有效的 TNF-α 抑制剂,IC50 为 42 μM。 | ||||
| GC64936 | TD52 dihydrochloride | - | >98.00% | |
A derivative of erlotinib | ||||
| GC64938 | AZD-7648 | 2230820-11-6 | >99.50% | |
An inhibitor of DNA-PK | ||||
| GC64946 | SRT 2183 | 1001908-89-9 | >98.00% | |
SRT2183 is a small-molecule activator of the sirtuin subtype SIRT1, currently being developed by Sirtris Pharmaceuticals. | ||||
| GC64951 | GSK963 | 2049868-46-2 | >99.00% | |
GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10?000-fold selective for RIP1 over 339 other kinases. | ||||
| GC64971 | DDO-7263 | 2254004-96-9 | >99.00% | |
DDO-7263 是一种 1,2,4-Oxadiazole 衍生物,是一种有效的 Nrf2-ARE 激活剂。DDO-7263 通过与 Rpn6 结合上调 Nrf2,从而阻断 26S 蛋白酶体的组装和随后泛素化 Nrf2 的降解。DDO-7263 诱导 Nrf2 易位进入细胞核。DDO-7263 抑制 NLRP3 炎性体激活。DDO-7263 具有抗炎活性,并且有潜力用于神经退行性疾病(例如帕金森病 (PD)) 的研究。 | ||||
| GC64980 | MV1 | 1001600-54-9 | >99.00% | |
MV1 是凋亡抑制因子 IAP 的拮抗剂,与 HaloTag 配体结合,导致 HaloTag 融合蛋白的蛋白敲除。 | ||||
| GC64992 | YH-306 | 1373764-75-0 | >98.00% | |
YH-306 是一种抗肿瘤剂。YH-306 通过 FAK 通路抑制结直肠肿瘤的生长和转移。 YH-306 显着抑制结直肠癌细胞的迁移和侵袭。YH-306 有效抑制不受抑制的增殖并诱导细胞凋亡 (apoptosis)。YH-306 抑制 FAK、c-Src、桩蛋白和 PI3K、Rac1 的激活以及 MMP2 和 MMP9 的表达。YH-306 还抑制肌动蛋白相关蛋白 (Arp2/3) 复合物介导的肌动蛋白聚合。 | ||||
| GC64993 | Chicoric acid | 6537-80-0 | >98.00% | |
Chicoric acid是一种羟基肉桂酸,属于苯丙醇类有机化合物,存在于菊苣、 蒲公英和罗勒等多种植物中,具有抗氧化、抗炎、抗糖尿病、抗病毒等多种生物活性。 | ||||
| GC64995 | RIPGBM | 355406-76-7 | >99.00% | |
A prodrug of cRIPGBM | ||||
| GC65004 | Apostatin-1 | 2559703-06-7 | >99.00% | |
Apostatin-1 (Apt-1) is a novel TRADD inhibitor. Apostatin-1 binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N). Apostatin-1 inhibits bortezomib-induced apoptosis and RIPK1-dependent apoptosis (RDA) with an IC50 of about 1 μM. | ||||
| GC65010 | Bortezomib-d8 | - | >98.00% | |
Bortezomib-d8 (PS-341-d8) 是 Bortezomib 的氘代物。Bortezomib (PS-341) 是一种可逆性和选择性的蛋白酶体 (proteasome) 抑制剂,通过靶向苏氨酸残基有效抑制 20S 蛋白酶体 (Ki=0.6 nM)。Bortezomib 破坏细胞周期、诱导细胞凋亡以及抑制核因子 NF-κB。Bortezomib 是第一种蛋白酶体抑制剂,具有抗癌活性。 | ||||
| GC65031 | Belimumab | 356547-88-1 | - | |
Belimumab (LymphoStat B) 是一种人 IgG1Λ 单克隆抗体,可抑制 B 细胞激活因子 (BAFF)。Belimumab 可用于系统性红斑狼疮 (SLE) 研究。 | ||||
| GC65033 | Tislelizumab | 1858168-59-8 | >97.50% | |
Tislelizumab 是一种对 PD-1 受体具有高结合亲和力的单克隆抗体,可最大限度地减少 Fcγ 受体与巨噬细胞的结合,从而消除抗体依赖性吞噬作用,这是一种 T 细胞清除机制,可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。 | ||||
